These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 11365894)
21. Standard treatments for HIV, Spring 1997. Smith D AIDS Treat News; 1997 Apr; (No 269):4-5. PubMed ID: 11364255 [TBL] [Abstract][Full Text] [Related]
22. Update from the 5th Conference on Retroviruses and Opportunistic Infections. Vazquez E Posit Aware; 1998; 9(3):21-3. PubMed ID: 11365483 [TBL] [Abstract][Full Text] [Related]
23. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent]. Allerg Immunol (Paris); 1998 Apr; 30(4):123-4. PubMed ID: 9631694 [No Abstract] [Full Text] [Related]
24. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Vila J; Nugier F; Barguès G; Vallet T; Peyramond D; Hamedi-Sangsari F; Seigneurin JM Lancet; 1997 Aug; 350(9078):635-6. PubMed ID: 9288048 [No Abstract] [Full Text] [Related]
25. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy. Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM; Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756 [TBL] [Abstract][Full Text] [Related]
26. Crixivan reduces viral load. AIDS Patient Care STDS; 1996 Feb; 10(1):50. PubMed ID: 11361665 [No Abstract] [Full Text] [Related]
27. [Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV]. Gavazzi G; Richallet G; Morand P; Bouchard O; Bosseray A; Leclercq P; Micoud M Pathol Biol (Paris); 1998 Jun; 46(6):412-5. PubMed ID: 9769871 [TBL] [Abstract][Full Text] [Related]
28. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy. Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885 [No Abstract] [Full Text] [Related]
29. Antiviral update. PI Perspect; 1996 Nov; (No 20):8-9. PubMed ID: 11363972 [TBL] [Abstract][Full Text] [Related]
30. Interrupting HAART; Hydroxyurea; five+ drug therapy - report from the RIGHT Conference. Levin J AIDS Treat News; 1999 May; (No 318):3-4. PubMed ID: 11366456 [TBL] [Abstract][Full Text] [Related]
31. Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects. Lori F; Lisziewicz J Antivir Ther; 1999; 4 Suppl 3():101-8. PubMed ID: 16021881 [TBL] [Abstract][Full Text] [Related]
32. Looking past two drugs, looking past three? Mascolini M J Int Assoc Physicians AIDS Care; 1997 Feb; 3(2):9-15, 18-22, 46. PubMed ID: 11364100 [TBL] [Abstract][Full Text] [Related]
34. Use of hydroxyurea in heavily pretreated patients with HIV infection. Hermans P; De Wit S; Sommereijns B; O'Doherty E; Clumeck N Antivir Ther; 1999; 4 Suppl 3():19-22. PubMed ID: 16021867 [TBL] [Abstract][Full Text] [Related]
35. Is Hydroxyurea for real? Mascolini M J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731 [TBL] [Abstract][Full Text] [Related]
36. HIV treatment options. Smith D AIDS Treat News; 1998 May; (No 294):4-5. PubMed ID: 11365404 [TBL] [Abstract][Full Text] [Related]